{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:30:12Z","timestamp":1792884612632,"version":"4.5.0"},"reference-count":98,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boston Children\u2019s Hospital Translational Research Program (TRP)"},{"name":"Wong Family Award in Translational Oncology"},{"name":"Alex\u2019s Lemonade Stand Foundation"},{"name":"Hyundai Hope on Wheels Scholar"},{"name":"Julia\u2019s Legacy of Hope St. Baldrick\u2019s Foundation Consortium Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>IKZF1 encodes the transcription factor IKAROS, a zinc finger DNA-binding protein with a key role in lymphoid lineage development. IKAROS plays a critical role in the development of lineage-restricted mature lymphocytes. Deletions within IKZF1 in B-cell acute lymphoblastic leukemia (B-ALL) lead to a loss of normal IKAROS function, conferring leukemic stem cell properties, including self-renewal and subsequent uncontrolled growth. IKZF1 deletions are associated with treatment resistance and inferior outcomes. Early identification of IKZF1 deletions in B-ALL may inform the intensification of therapy and other potential treatment strategies to improve outcomes in this high-risk leukemia.<\/jats:p>","DOI":"10.3390\/biomedicines12010089","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T13:02:58Z","timestamp":1704114178000},"page":"89","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6891-8497","authenticated-orcid":false,"given":"Jonathan","family":"Paolino","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA"},{"name":"Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison K.","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Boston Children\u2019s Hospital, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian H.","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Pathology, Boston Children\u2019s Hospital, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-0216","authenticated-orcid":false,"given":"Yana","family":"Pikman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA"},{"name":"Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcancer.2020.10.013","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities","volume":"84","author":"Tran","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/bloodadvances.2017014704","article-title":"Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia","volume":"2","author":"Tran","year":"2018","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/cam4.87","article-title":"IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan","volume":"2","author":"Asai","year":"2013","journal-title":"Cancer Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0092-8674(94)90407-3","article-title":"The Ikaros gene is required for the development of all lymphoid lineages","volume":"79","author":"Georgopoulos","year":"1994","journal-title":"Cell"},{"key":"ref_9","first-page":"8292","article-title":"The Ikaros gene encodes a family of functionally diverse zinc finger DNA-binding proteins","volume":"14","author":"Georgopoulos","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1101\/gad.12.6.782","article-title":"Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin","volume":"12","author":"Hahm","year":"1998","journal-title":"Genes Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/emboj\/16.8.2004","article-title":"Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation","volume":"16","author":"Morgan","year":"1997","journal-title":"EMBO J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0014-5793(99)00265-3","article-title":"Eos: A novel member of the Ikaros gene family expressed predominantly in the developing nervous system","volume":"447","author":"Honma","year":"1999","journal-title":"FEBS Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"38347","DOI":"10.1074\/jbc.M005457200","article-title":"Eos and Pegasus, Two Members of the Ikaros Family of Proteins with Distinct DNA Binding Activities","volume":"275","author":"Perdomo","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1101\/gad.283762.116","article-title":"Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia","volume":"30","author":"Hu","year":"2016","journal-title":"Genes Dev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1101\/gad.297002.117","article-title":"The making of a lymphocyte: The choice among disparate cell fates and the IKAROS enigma","volume":"31","author":"Georgopoulos","year":"2017","journal-title":"Genes Dev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.immuni.2009.01.014","article-title":"Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells","volume":"30","author":"Ng","year":"2009","journal-title":"Immunity"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ni1314","article-title":"Early hematopoietic lineage restrictions directed by Ikaros","volume":"7","author":"Yoshida","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1002\/j.1460-2075.1996.tb00920.x","article-title":"Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development","volume":"15","author":"Sun","year":"1996","journal-title":"EMBO J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1128\/MCB.24.7.2797-2807.2004","article-title":"Phosphorylation controls Ikaros\u2019s ability to negatively regulate the G(1)-S transition","volume":"24","author":"Maki","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1101\/gad.1040502","article-title":"A common mechanism for mitotic inactivation of C2H2 zinc finger DNA-binding domains","volume":"16","author":"Dovat","year":"2002","journal-title":"Genes Dev."},{"key":"ref_21","first-page":"7111","article-title":"The lymphoid transcription factor LyF-1 is encoded by specific, alternatively spliced mRNAs derived from the Ikaros gene","volume":"14","author":"Hahm","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1073\/pnas.95.2.657","article-title":"Hematopoietic stem cells and lymphoid progenitors express different Ikaros isoforms, and Ikaros is localized to heterochromatin in immature lymphocytes","volume":"95","author":"Klug","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Affar, M., Bottardi, S., Quansah, N., Lemari\u00e9, M., Ram\u00f3n, A.C., Affar, E.B., and Milot, E. (2023). IKAROS: From chromatin organization to transcriptional elongation control. Cell Death Differ., epub ahead of print.","DOI":"10.1038\/s41418-023-01212-2"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/ni.2821","article-title":"Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia","volume":"15","author":"Joshi","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ni.2150","article-title":"Harnessing of the nucleosome-remodeling-deacetylase complex controls lymphocyte development and prevents leukemogenesis","volume":"13","author":"Zhang","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1074-7613(00)80034-5","article-title":"Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes","volume":"10","author":"Kim","year":"1999","journal-title":"Immunity"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"30227","DOI":"10.1074\/jbc.M702541200","article-title":"Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes","volume":"282","author":"Sridharan","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.trsl.2014.05.003","article-title":"The nucleosome remodeling and deacetylase complex in development and disease","volume":"165","author":"Basta","year":"2015","journal-title":"Transl. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1016\/j.cell.2023.10.023","article-title":"Lineage-specific 3D genome organization is assembled at multiple scales by IKAROS","volume":"186","author":"Hu","year":"2023","journal-title":"Cell"},{"key":"ref_30","first-page":"1","article-title":"Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia","volume":"3","author":"Kastner","year":"2013","journal-title":"Am. J. Blood Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2008-08-173963","article-title":"Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: On behalf of Gruppo Italiano Malattie Ematologiche dell\u2019Adulto Acute Leukemia Working Party (GIMEMA AL WP)","volume":"114","author":"Iacobucci","year":"2009","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","article-title":"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL","volume":"122","author":"Waanders","year":"2013","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/pbc.22944","article-title":"Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children\u2019s Oncology Group trial P9906","volume":"57","author":"Bowman","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ccell.2015.07.016","article-title":"Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia","volume":"28","author":"Churchman","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41375-022-01806-8","article-title":"Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia","volume":"37","author":"Ryan","year":"2023","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jmoldx.2023.06.007","article-title":"Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors","volume":"25","author":"Tsai","year":"2023","journal-title":"J. Mol. Diagn."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"23922","DOI":"10.1074\/jbc.M513461200","article-title":"A conserved 12-amino acid motif in Sall1 recruits the nucleosome remodeling and deacetylase corepressor complex","volume":"281","author":"Lauberth","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_41","first-page":"5074","article-title":"A non-canonical role for Rgnef in promoting integrin-stimulated focal adhesion kinase activation","volume":"126","author":"Miller","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11790","DOI":"10.1038\/ncomms11790","article-title":"Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia","volume":"7","author":"Henningsson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/leu.2009.251","article-title":"Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia","volume":"24","author":"Schmiegelow","year":"2010","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.semdp.2023.04.003","article-title":"Emerging molecular subtypes and therapies in acute lymphoblastic leukemia","volume":"40","author":"Davis","year":"2023","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ccell.2018.03.021","article-title":"Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia","volume":"33","author":"Churchman","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/bloodadvances.2018016584","article-title":"Refining risk classification in childhood B acute lymphoblastic leukemia: Results of DFCI ALL Consortium Protocol 05-001","volume":"2","author":"Vrooman","year":"2018","journal-title":"Blood Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/leu.2009.258","article-title":"Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004","volume":"24","author":"Kamps","year":"2010","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2010.039735","article-title":"The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97)","volume":"96","author":"Escherich","year":"2011","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1182\/bloodadvances.2019000576","article-title":"Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity","volume":"3","author":"Schramm","year":"2019","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41375-021-01133-4","article-title":"Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic\/Latino children-a novel health disparity","volume":"35","author":"Raca","year":"2021","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1182\/blood-2022-167965","article-title":"Racial and Ethnic Disparities in Childhood Acute Lymphoblastic Leukemia Risk Due to an IKZF1 Noncoding Regulatory Variant","volume":"140","author":"Wahlster","year":"2022","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1(plus) Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41375-019-0670-y","article-title":"Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: Long-term results of the international AIEOP-BFM ALL 2000 trial","volume":"34","author":"Attarbaschi","year":"2020","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e30313","DOI":"10.1002\/pbc.30313","article-title":"The prognostic value of IKZF1(plus) in B-cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial","volume":"70","author":"Kicinski","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3324\/haematol.2014.103507","article-title":"Dexamethasone (6 mg\/m2\/day) and prednisolone (60 mg\/m2\/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial","volume":"99","author":"Domenech","year":"2014","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/leu.2015.134","article-title":"IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: Results of the EORTC Children\u2019s Leukemia Group study 58951","volume":"29","author":"Clappier","year":"2015","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: Insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clml.2017.03.299","article-title":"Philadelphia Chromosome-like Acute Lymphoblastic Leukemia","volume":"17","author":"Pui","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJM200004063421402","article-title":"Outcome of Treatment in Children with Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia","volume":"342","author":"Valsecchi","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: A GIMEMA AL WP report","volume":"27","author":"Martinelli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","article-title":"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","volume":"123","author":"Zaliova","year":"2014","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3324\/haematol.2018.196055","article-title":"Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"104","author":"Fedullo","year":"2019","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study","volume":"10","author":"Cheok","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e875","DOI":"10.1097\/HS9.0000000000000875","article-title":"The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia","volume":"7","author":"Enshaei","year":"2023","journal-title":"Hemasphere"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/leu.2013.277","article-title":"An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions","volume":"28","author":"Clappier","year":"2014","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/ng.3691","article-title":"Deregulation of DUX4 and ERG in acute lymphoblastic leukemia","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/leu.2013.282","article-title":"ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia","volume":"28","author":"Zaliova","year":"2014","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hon.2791","article-title":"Pediatric randomized trial EORTC CLG 58951: Outcome for adolescent population with acute lymphoblastic leukemia","volume":"38","author":"Arfeuille","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/gcc.20818","article-title":"Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia","volume":"49","author":"Schwab","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jmoldx.2017.05.004","article-title":"Digital Multiplex Ligation-Dependent Probe Amplification for Detection of Key Copy Number Alterations in T- and B-Cell Lymphoblastic Leukemia","volume":"19","author":"Zondervan","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jmoldx.2018.02.005","article-title":"Development of a Fluorescence in Situ Hybridization Probe for Detecting IKZF1 Deletion Mutations in Patients with Acute Lymphoblastic Leukemia","volume":"20","author":"Hashiguchi","year":"2018","journal-title":"J. Mol. Diagn."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41598-019-56972-0","article-title":"Concordance of copy number abnormality detection using SNP arrays and Multiplex Ligation-dependent Probe Amplification (MLPA) in acute lymphoblastic leukaemia","volume":"10","author":"Bashton","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3324\/haematol.2012.073965","article-title":"Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia","volume":"98","author":"Caye","year":"2013","journal-title":"Haematologica"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41416-022-01806-6","article-title":"Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions","volume":"127","author":"Venn","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1182\/bloodadvances.2019001008","article-title":"The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia","volume":"4","author":"Brown","year":"2020","journal-title":"Blood Adv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/bloodadvances.2021005634","article-title":"Whole-transcriptome analysis in acute lymphoblastic leukemia: A report from the DFCI ALL Consortium Protocol 16-001","volume":"6","author":"Tran","year":"2022","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rehn, J., Mayoh, C., Heatley, S.L., McClure, B.J., Eadie, L.N., Schutz, C., Yeung, D.T., Cowley, M.J., Breen, J., and White, D.L. (2022). RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL). PLoS Genet., 18.","DOI":"10.1371\/journal.pgen.1010300"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/bloodadvances.2022009179","article-title":"Classification and genetics of pediatric B-other acute lymphoblastic leukemia by targeted RNA sequencing","volume":"7","author":"Migita","year":"2023","journal-title":"Blood Adv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"130","DOI":"10.12688\/f1000research.129490.1","article-title":"Toblerone: Detecting exon deletion events in cancer using RNA-seq","volume":"12","author":"Lonsdale","year":"2023","journal-title":"F1000Res"},{"key":"ref_82","first-page":"3046","article-title":"Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations","volume":"106","author":"Yu","year":"2021","journal-title":"Haematologica"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1200\/JCO.22.02705","article-title":"Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups","volume":"41","author":"Pieters","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2018.78.3050","article-title":"Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study","volume":"36","author":"Yeoh","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.phoj.2020.03.009","article-title":"Malaysia-Singapore (MASPORE) leukaemia study group: From common history to successful collaboration","volume":"5","author":"Ariffin","year":"2020","journal-title":"Pediatr. Hematol. Oncol. J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/leu.2017.154","article-title":"Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95","volume":"31","author":"Hinze","year":"2017","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1182\/blood-2022-164699","article-title":"A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521\/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations","volume":"140","author":"Tasian","year":"2022","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1182\/bloodadvances.2020002408","article-title":"Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities","volume":"5","author":"Rogers","year":"2021","journal-title":"Blood Adv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2015.359","article-title":"Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia","volume":"30","author":"Marke","year":"2016","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/leu.2016.128","article-title":"IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients showing prednisolone resistance","volume":"30","author":"Imamura","year":"2016","journal-title":"Leukemia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"905665","DOI":"10.3389\/fonc.2022.905665","article-title":"Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways","volume":"12","author":"Butler","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1200\/JCO.2022.40.16_suppl.7033","article-title":"Targeting signaling pathways vulnerabilities for the treatment of IKZF1-deleted ph-negative B lymphoblastic leukemia","volume":"40","author":"Gupta","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2015-06-651505","article-title":"Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia","volume":"126","author":"Song","year":"2015","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/leu.2015.331","article-title":"Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia","volume":"30","author":"Song","year":"2016","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood.2019002655","article-title":"IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia","volume":"136","author":"Song","year":"2020","journal-title":"Blood"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/12\/1\/89\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:37:51Z","timestamp":1760103471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/12\/1\/89"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["biomedicines12010089"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines12010089","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}